sorafenib has been researched along with ly-2157299 in 5 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ly-2157299) | Trials (ly-2157299) | Recent Studies (post-2010) (ly-2157299) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 126 | 21 | 124 |
| Protein | Taxonomy | sorafenib (IC50) | ly-2157299 (IC50) |
|---|---|---|---|
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | 0.044 | |
| Mitogen-activated protein kinase kinase kinase kinase 4 | Homo sapiens (human) | 0.2716 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.442 | |
| Activin receptor type-1B | Homo sapiens (human) | 0.199 | |
| TGF-beta receptor type-1 | Homo sapiens (human) | 0.0973 | |
| TGF-beta receptor type-2 | Homo sapiens (human) | 1.3 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.405 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.4736 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Albuquerque, M; Benhadji, KA; de Gramont, A; Dos Santos, C; Faivre, S; Neuzillet, C; Paradis, V; Raymond, E; Serova, M; Tijeras-Raballand, A | 1 |
| Han, C; Ungerleider, N; Wu, T; Yao, L; Zhang, J | 1 |
| Benhadji, KA; Ikeda, M; Inoue, K; Lahn, MMF; Morimoto, M; Sakai, D; Tajimi, M | 1 |
| Assenat, E; Benhadji, KA; Cleverly, A; Faivre, S; Galle, PR; Gane, E; Giannelli, G; Gueorguieva, I; Hourmand, IO; Kelley, RK; Lahn, M; Merle, P; Siebler, J; Zhao, Y | 1 |
2 trial(s) available for sorafenib and ly-2157299
| Article | Year |
|---|---|
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Pyrazoles; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Sorafenib; Tissue Distribution | 2019 |
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Carcinoma, Hepatocellular; Case-Control Studies; Disease Progression; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Quinolines; Receptors, Transforming Growth Factor beta; Safety; Sorafenib; Transforming Growth Factor beta1; Treatment Outcome | 2019 |
3 other study(ies) available for sorafenib and ly-2157299
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hep G2 Cells; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyrroles; Quinolines; Signal Transduction; Sorafenib; Sunitinib; Transforming Growth Factor beta1 | 2015 |
TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Quinolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Transforming Growth Factor beta | 2017 |